Cytotoxic Payloads for AntibodyDrug Conjugates
Antibody-drug conjugates (ADCs) represent one of the most promising and exciting areas of anticancer drug discovery. Five ADCs are now approved in the US and EU [i.e., ado-trastuzumab emtansine (Kadcyla(TM)), brentuximab vedotin (Adcetris(TM)), inotuzumab ozogamicin (Besponsa(TM)), gemtuzumab ozogamicin (Mylotarg(TM)) and moxetumomab pasudotox-tdfk (Lumoxiti®)] and over 70 others are in various stages of clinical development, with impressive interim results being reported for many. The technology is based on the concept of delivering a cytotoxic payload selectively to cancer cells by attaching it to an antibody targeted to antigens on the cel…
Mehr
CHF 312.15
Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)
Versandkostenfrei
Produktdetails
Weitere Autoren: Jackson, Paul J M (Hrsg.)
- ISBN: 978-1-78801-845-6
- EAN: 9781788018456
- Produktnummer: 31966405
- Verlag: Royal Society of Chemistry
- Sprache: Englisch
- Erscheinungsjahr: 2019
- Seitenangabe: 480 S.
- Plattform: EPUB
- Masse: 62'267 KB
- Auflage: 1. Auflage
2 weitere Werke von David E (Hrsg.) Thurston:
Bewertungen
Anmelden